ArticleCureus2026
Cochlear Implantation Following Neurobrucellosis-Related Bilateral Profound Sensorineural Hearing Loss: A Case Report and Literature Review.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brucellosis is the most common bacterial zoonosis worldwide, and neurological involvement - neurobrucellosis - can cause bilateral profound sensorineural hearing loss (SNHL) that does not respond to antibiotic therapy. We report cochlear implantation (CI) outcomes in a 60-year-old man with confirmed neurobrucellosis who developed bilateral profound SNHL that provided no functional benefit after a six-month binaural hearing aid trial. Preoperative temporal bone computed tomography and magnetic resonance imaging confirmed intact cochlear anatomy with no labyrinthitis ossificans on either modality. Right-ear CI was performed after an infectious disease consultation confirmed sustained disease remission. At 12-month follow-up, sound-field thresholds were 40 dB hearing level (HL) at 500 Hz and 45-50 dB HL at 1,000-4,000 Hz. The patient was able to follow face-to-face conversations without lip-reading. We also review all previously published cases in which CI was performed or considered in this setting, highlighting the consistent absence of labyrinthitis ossificans, unlike most other bacterial causes of deafness, which facilitates full electrode insertion and supports favorable outcomes. CI is safe and effective for neurobrucellosis patients with bilateral profound SNHL, and confirmed disease remission before surgery is a mandatory prerequisite.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.